- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Maze Therapeutics stock price target reiterated at $60 by H.C. Wainwright | 3 | Investing.com | ||
| 19.12.25 | Guggenheim raises Maze Therapeutics stock price target to $46 on CKD program | 1 | Investing.com | ||
| 18.12.25 | Leerink Partners raises Maze Therapeutics stock price target to $50 on AMKD study | 2 | Investing.com | ||
| 18.12.25 | Maze Therapeutics: Leerink Partners hebt Kursziel vor wichtigen Studiendaten auf 50 US-Dollar an | 10 | Investing.com Deutsch | ||
| 04.12.25 | H.C. Wainwright hebt Kursziel für Maze Therapeutics auf 60 US-Dollar an | 9 | Investing.com Deutsch | ||
| 04.12.25 | Maze Therapeutics stock rating initiated at Overweight by Wells Fargo | 4 | Investing.com | ||
| 13.11.25 | Raymond James startet Coverage für Maze Therapeutics mit "Outperform" | 7 | Investing.com Deutsch | ||
| 13.11.25 | Raymond James initiates Maze Therapeutics stock with Outperform rating | 3 | Investing.com | ||
| MAZE THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 06.11.25 | Maze Therapeutics, Inc.: Maze Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights | 144 | GlobeNewswire (Europe) | First-in-human data from Phase 1 trial of MZE782 support best- and first-in-class potential; two Phase 2 proof-of-concept trials in phenylketonuria (PKU) and chronic kidney disease (CKD) expected... ► Artikel lesen | |
| 06.11.25 | Maze Therapeutics to present data on kidney disease therapies at ASN meeting | 9 | Investing.com | ||
| 17.10.25 | Maze Therapeutics files to sell 9.23M shares of common stock for holders | 2 | Seeking Alpha | ||
| 17.10.25 | Maze Therapeutics, Inc. - S-1, General form for registration of securities | 2 | SEC Filings | ||
| 06.10.25 | Maze Therapeutics, Inc. - 8-K, Current Report | 4 | SEC Filings | ||
| 06.10.25 | Maze Therapeutics appoints Hervé Hoppenot as board chairman | 10 | Investing.com | ||
| 06.10.25 | Maze Therapeutics, Inc.: Maze Therapeutics Appoints Industry Veteran Hervé Hoppenot as Chairman of the Board of Directors | 218 | GlobeNewswire (Europe) | SOUTH SAN FRANCISCO, Calif., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for... ► Artikel lesen | |
| 03.10.25 | Maze Therapeutics stock rating reiterated at Buy by H.C. Wainwright | 1 | Investing.com | ||
| 03.10.25 | Maze Therapeutics: H.C. Wainwright bestätigt "Buy"-Rating und sieht deutliches Aufwärtspotenzial | 4 | Investing.com Deutsch | ||
| 19.09.25 | Maze Therapeutics, Inc. (MAZE): A Bull Case Theory | 18 | Insider Monkey | ||
| 15.09.25 | Maze Therapeutics stock price target raised to $34 at Guggenheim on promising PKU data | 3 | Investing.com | ||
| 15.09.25 | Maze Therapeutics: Guggenheim erhöht Kursziel nach vielversprechenden PKU-Studiendaten deutlich auf 34 $ | 1 | Investing.com Deutsch |
1 2 3 Weiter >>
44 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ABIVAX | 94,40 | 0,00 % | Abivax-Aktie: AstraZeneca soll Übernahmeversuch starten | Einem brandaktuellen Bericht der französischen Le Lettre zufolge prüft der britische Pharmariese AstraZeneca ein Übernahmeangebot für das französische Biotechunternehmen Abivax. Zuvor galt insbesondere... ► Artikel lesen | |
| CYTOKINETICS | 54,00 | -1,82 % | Cytokinetics, Incorporated: Cytokinetics Announces MYQORZO (aficamten) Now Available in the U.S. for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy to Improve Functional Capacity and Symptoms | MYQORZO, a Cardiac Myosin Inhibitor, Directly Addresses Underlying Hypercontractility Associated with Obstructive HCM SOUTH SAN FRANCISCO, Calif., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Cytokinetics,... ► Artikel lesen | |
| CYTOMX THERAPEUTICS | 4,820 | +0,37 % | SD-Tipp CytomX: Was tun nach +1.438% in 10 Monaten? | Unsere Aktien-Empfehlung CytomX Therapeutics erlebt derzeit einen außergewöhnlich starken Kursverlauf. Innerhalb kurzer Zeit hat sich das Papier von einem lange übersehenen Small-Cap-Titel zu einem... ► Artikel lesen | |
| UNIQURE | 19,995 | +1,14 % | What Analysts Are Saying About uniQure Stock | ||
| PALISADE BIO | 1,620 | 0,00 % | Palisade Bio, Inc.: Palisade Bio Appoints Leading Global IBD Experts, Laurent Peyrin-Biroulet, MD, PhD and David T. Rubin, MD, to Its Clinical Advisory Board | Internationally recognized leaders in inflammatory bowel disease bring deep expertise spanning ulcerative colitis, Crohn's disease, and late-stage clinical trial design Appointments strengthen Palisade... ► Artikel lesen | |
| TENAX THERAPEUTICS | 2,770 | -100,00 % | Tenax Therapeutics, Inc.: Tenax Therapeutics Announces Result of Prespecifed Blinded Sample Size Assessment | Planned Review of Standard Deviation Demonstrates No Need to Increase Size of Ongoing LEVEL Study LEVEL On Track to Complete Enrollment in First Half of 2026; Topline Data Expected in Second Half... ► Artikel lesen | |
| AMYLYX PHARMACEUTICALS | 14,850 | 0,00 % | Gubra A/S: Amylyx Pharmaceuticals Announces Nomination of AMX0318 as a Novel, Long-Acting GLP-1 Receptor Antagonist Development Candidate, Identified in Collaboration with Gubra | AMX0318 selected as development candidate after meeting key criteria, demonstrating a robust chemical stability profile, strong in vitro potency, evidence of in vivo efficacy and tolerability, high... ► Artikel lesen | |
| NURIX THERAPEUTICS | 17,580 | 0,00 % | Nurix Therapeutics, Inc.: Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides a Corporate Update | First patients dosed in DAYBreak registrational program for bexobrutideg in relapsed/refractory CLLPresented Phase 1 results at ASH 2025 that support bexobrutideg's potential best-in-class profile... ► Artikel lesen | |
| CELCUITY | 88,00 | -6,38 % | Celcuity Inc.: Celcuity Announces FDA Acceptance of New Drug Application for Gedatolisib in HR+/HER2-/PIK3CA Wild-Type Advanced Breast Cancer | FDA grants Priority Review and assigns a PDUFA goal date of July 17, 2026 MINNEAPOLIS, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing... ► Artikel lesen | |
| TREVI THERAPEUTICS | 10,690 | 0,00 % | Trevi Therapeutics, Inc.: Trevi Therapeutics Announces Appointment of David Hastings as Chief Financial Officer | Experienced biotech CFO to lead financial strategy and contribute to the Company's next stage of growth
NEW HAVEN, Conn., Dec. 4, 2025 /PRNewswire/ -- Trevi Therapeutics... ► Artikel lesen | |
| PEPGEN | 5,215 | 0,00 % | PepGen Inc.: PepGen Announces Oral Presentations at the 30th Annual International Congress of the World Muscle Society | PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and... ► Artikel lesen | |
| ALUMIS | 26,840 | 0,00 % | Alumis Inc.: Alumis Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares | SOUTH SAN FRANCISCO, Calif., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing next-generation targeted therapies for patients with... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 15,400 | 0,00 % | Summit Therapeutics Inc. - 8-K, Current Report | ||
| COGENT BIOSCIENCES | 37,650 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Breakthrough Therapy Designation for Bezuclastinib in Combination with Sunitinib for Patients with Gastrointestinal Stromal Tumors (GIST) | - Cogent will submit the PEAK New Drug Application (NDA) under previously announced RTOR designation; on track to complete NDA submission in April 2026 WALTHAM, Mass. and BOULDER, Colo., Jan. 26... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 69,98 | 0,00 % | Apogee Therapeutics: Empfehlung liefert +129% in 6 Monaten | Im Juli letzten Jahres präsentierten wir im Rahmen unserer Berichterstattung und innerhalb unserer erfolgreichen Community die Aktie von Apogee Therapeutics als heißen Kauftipp. Grundlage war eine ausgeprägte... ► Artikel lesen |
MAZE THERAPEUTICS INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 45,040 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MAZE THERAPEUTICS INC finden Sie auf Wallstreet Online.